<DOC>
	<DOCNO>NCT00350779</DOCNO>
	<brief_summary>A clinical study determine safety efficacy sitagliptin patient Type 2 Diabetes Mellitus inadequate glycemic control metformin/peroxisome proliferator-activated receptor gamma ( PPARg ) agonist combination therapy .</brief_summary>
	<brief_title>Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on ( 0431-052 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Patient type 2 diabetes mellitus Patient inadequately control take two oral antidiabetic medication Patient history type 1 diabetes mellitus history ketoacidosis Patient require insulin therapy within prior 3 month Patient take Byetta ( R ) ( exenatide ) within prior 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>